Status:
COMPLETED
Vivax Elimination With Tafenoquine (VET) Study
Lead Sponsor:
Shoklo Malaria Research Unit
Collaborating Sponsors:
Mahidol Oxford Tropical Medicine Research Unit
Conditions:
Malaria
Malaria, Vivax
Eligibility:
All Genders
6+ years
Phase:
PHASE4
Brief Summary
Theoretically, so long as there is a sink-source for malaria, transmission could be sustained at very low level (even at sub-microscopic oscillation) and reintroduce malaria either as sporadic cases o...
Detailed Description
Malaria remains a major health concern in Myanmar, particularly in Karen State along the Myanmar-Thailand border, where disruptions in health services have led to a significant increase in cases. To a...
Eligibility Criteria
Inclusion
- All village residence, aged \>6 months who agrees to participate in the research.
Exclusion
- People who refuse to participate
- People who are hypersensitive to Tafenoquine or Chloroquine
- Critically ill patient
Key Trial Info
Start Date :
February 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 4 2025
Estimated Enrollment :
1242 Patients enrolled
Trial Details
Trial ID
NCT06575647
Start Date
February 19 2025
End Date
October 4 2025
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shoklo Malaria Research Unit (SMRU)
Mae Sot, Changwat Tak, Thailand